1453-P: Islet Autoantibody–Positive General Population Individuals Have Smaller Pancreas Volume Compared with Control Individuals

Introduction 40 Stage 1, 26 Stage 2, 12 unknown Stage), individuals with T1D (n=93), and control individuals without T1D (n=90). PVI is normalized for weight which accounts for potential confounding from age or sex. Results: Most AAb+ general population individuals were male (8/10) and non-Hispanic white (9/10). Most (8/10) were Stage 1, and 2 were Stage 2 T1D. Age at MRI was 15.6 ± 2.8 years with a mean HbA1c 5.3 ± 0.3 %, fasting glucose 87 ± 5 mg/dl and 2-hour OGTT glucose 103 ± 32 mg/dl. AAb+ general population individuals had a lower PVI 0.75 ± 0.17 ml/kg compared to control individuals 0.96 ± 0.25 ml/kg (p=0.03). The PVI of AAb+ general population individuals was similar to that of AAb+ FDR 0.85 ± 0.26 ml/kg (p=0.21). Individuals with T1D had a lower PVI 0.60 ± 0.24 ml/kg than AAb+ FDR (p0.0001) but not AAb+ general population individuals (p=0.14). Conclusion: AAb+ general population individuals and AAb+ FDR individuals have smaller PVI compared to control individuals without T1D. Individuals with T1D have a smaller PVI than AAb+ FDR. More study on pancreas size prior to T1D onset may help inform future prediction and prevention studies. Disclosure T.M. Triolo: None. J. Virostko: None. J.M. Williams: None. H.C. Broncucia: None. M.A. Hilmes: None. M. Rewers: Advisory Panel; Sanofi. Other Relationship; Sanofi. Consultant; Janssen Pharmaceuticals, Inc. Research Support; Juvenile Diabetes Research Foundation (JDRF). Consultant; Provention Bio, Inc. Research Support; Hemsley Charitable Trust, National Institute of Diabetes and Digestive and Kidney Diseases. D.J. Moore: None. A.C. Powers: None. A. Steck: None. Funding NIDDK K23 DK136931